Schrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its holdings in Schrödinger, Inc. (NASDAQ:SDGR) by 17.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,279,313 shares of the company’s stock after buying an additional 334,131 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Schrödinger were worth $43,968,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Paradigm Asset Management Co. LLC purchased a new stake in Schrödinger during the 4th quarter worth $50,000. Quarry LP grew its stake in shares of Schrödinger by 1,150.0% in the third quarter. Quarry LP now owns 2,825 shares of the company’s stock valued at $52,000 after buying an additional 2,599 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock valued at $54,000 after buying an additional 1,305 shares during the period. KBC Group NV lifted its position in Schrödinger by 73.9% during the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock worth $84,000 after acquiring an additional 1,853 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new position in Schrödinger in the 3rd quarter worth approximately $151,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SDGR shares. Piper Sandler reduced their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. KeyCorp upped their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $32.29.

Insider Transactions at Schrödinger

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the sale, the chief financial officer now owns 27,544 shares of the company’s stock, valued at $599,357.44. This represents a 16.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.60% of the company’s stock.

Schrödinger Stock Down 4.5 %

Shares of Schrödinger stock opened at $18.03 on Friday. The business has a 50-day moving average price of $22.74 and a 200 day moving average price of $20.75. Schrödinger, Inc. has a fifty-two week low of $16.67 and a fifty-two week high of $29.15. The firm has a market cap of $1.32 billion, a P/E ratio of -7.71 and a beta of 1.77.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $88.32 million for the quarter, compared to analyst estimates of $83.20 million. As a group, equities research analysts anticipate that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.